Operator

Hello, and welcome to the Definium Therapeutics Phase III Emerge Top line results call. [Operator Instructions] As a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time.

I would now like to pass the call over to Rob Barrow, Chief Executive Officer. Please proceed.

Robert Barrow
CEO & Director

Hello, everyone, and thank you for joining us this morning. As the operator said, I'm Rob Barrow, CEO of Definium and joined today by our Chief Medical Officer, Dr. Dan Karlin; our Chief Financial Officer Brandi Roberts; and our Chief Commercial Officer, Matt Wiley. We couldn't be more excited to be here with you this morning to share the landmark results for Emerge.

Before we get started, please note that on today's call, we'll be making certain forward-looking statements. We'd encourage you to review our SEC filings for a discussion of the risks and uncertainties associated with these statements. Opportunities to share results like these today are exceedingly rare. We believe the findings being presented today has the potential to redefine what patients can expect in the treatment of major depressive disorder and position DT120